Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Johnson & Johnson (

A CEO contender left Johnson & Johnson. Was she penalized for saying she wanted the job?

The exit of a Johnson & Johnson exec raises an age-old question about women's ambition.

Fortune · Dec 7, 2023

His dad worked on the factory floor at Johnson & Johnson. Now he’s the CFO

Joe Wolk, with J&J for over 25 years, talks about his path and the company's focus on innovation.

Fortune · Dec 6, 2023

Breakthrough antidepressants with fewer side effects could help millions of Americans. Here's what the future of treatment may look like

As Americans are increasingly reaching for pharmaceutical solutions for depression—about one in eight U.S. adults takes antidepressants—scientists have been innovating novel treatments for it.

Fortune · Nov 4, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

Should You Invest in Johnson & Johnson (JNJ) Following Q3 Results

Johnson & Johnson’s (JNJ) third-quarter results impressed investors, as its earnings and revenue beat Wall Street estimates. Should investors consider investing in the stock following the solid third-quarter results? Read on to learn my view….

StockNews.com · Oct 24, 2023

3 Dividend Aristocrats to Defend Your Portfolio in Q4

In the midst of economic uncertainty, look to the likes of Procter & Gamble, Coca-Cola, and Johnson & Johnson as steadfast investment options, offering relative stability and reliable income for Q4 2023 and beyond.

Barchart · Oct 14, 2023

How big companies from EY to Johnson & Johnson are learning to master AI prompts

Embracing AI is the easy part—firms have already moved on to harder parts like making AI actually work for their business.

Fortune · Oct 13, 2023

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

StockNews.com · Oct 12, 2023

Read news from The Economist, FT, and more,
with one subscription

Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J CEO Joaquin Duato

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

Fortune · Oct 11, 2023

Three Stocks To Help You Through the Financial Roller Coaster!

The Middle East is back in focus as tensions broke. But, what can investors own to weather the storm?

Barchart · Oct 10, 2023

Travis Kelce shakes off Aaron Rodgers dig: ‘I’m fully comfortable with him calling me Mr. Pfizer’

Mr. Pfizer and his mustache are doing just fine.

USA Today Sports Media Group · Oct 6, 2023

Chiefs’ Travis Kelce Responds to Aaron Rodgers’s ‘Mr. Pfizer’ Jab

“Who knew I’d get into the vax wars with Aaron Rodgers, man?”

Sports Illustrated · Oct 6, 2023

Aaron Rodgers oddly called Travis Kelce ‘Mr. Pfizer’ despite playing for the Johnson & Johnson heir

Aaron Rodgers can be such a dork, man.

USA Today Sports Media Group · Oct 3, 2023

In rare interview, J&J CEO Joaquin Duato opens up about Baby Powder cancer lawsuits and the future of Kenvue

J&J CEO Joaquin Duato's interview on Baby Powder cancer lawsuits, Kenvue, and the COVID vaccine.

Fortune · Oct 3, 2023

Johnson & Johnson Stock Looks Like Good Value Now

Johnson & Johnson stock (JNJ) recently spun off its consumer Kenvue business, which trades separately under the symbol KVUE. However, JNJ stock has dipped and now looks like good value.

Barchart · Oct 3, 2023

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · Sep 28, 2023

Protect Your Returns With These 3 Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

Barchart · Sep 28, 2023

Protect Your Returns With These Three Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

AAP · Sep 21, 2023

Lawyers lose in better deal for pelvic mesh victims

A law firm that ran two class actions for women harmed by pelvic mesh implants will lose out on a $38.5 million cut of $405 million in settlement funds.

Fortune · Sep 15, 2023

This J&J exec sold Tylenol and Listerine. Now she runs its $27B medtech business

Ashley McEvoy pivoted from over-the-counter products to medical devices.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK · Sep 14, 2023

Johnson & Johnson is getting rid of its script logo after more than 130 years

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one

The Times of India · Sep 14, 2023

Cricketer Harmanpreet Kaur on TIME100 NEXT 2023 list of emerging leaders

NEW DELHI: Three notable Indians, including cricketer Harmanpreet Kaur, have earned a spot on TIME magazine's prestigious "2023 TIME100 Next: the Emerging Leaders Shaping the World" list. The list also featured Nandita Venkatesan and Vinu Daniel. It also featured Indian-origin Nabarun Dasgupta.

Reason · Sep 13, 2023

Fake Sudafed Is Bullshit, Just As You Suspected

Legal restrictions on pseudoephedrine have not reduced meth use, but they have driven people with colds or allergies toward substitutes that seem to be completely ineffective.

WEKU · Sep 13, 2023

A popular nasal decongestant doesn't actually relieve congestion, FDA advisers say

The FDA asked advisers to take another look at phenylephrine, which became the main drug in over-the-counter decongestants when medicines with an older ingredient were moved behind pharmacy counters.

Chicago Sun-Times · Sep 12, 2023

Popular nasal decongestant ingredient doesn’t relieve congestion, FDA advisers say

Advisers to the Food and Drug Administration voted unanimously on Tuesday against the effectiveness of the key drug phenylephrine found in popular versions of Sudafed, Dayquil and other medications stocked on store shelves.

The Independent UK · Sep 12, 2023

Popular nasal decongestant doesn't actually relieve congestion, FDA experts say

Government advisers say the leading decongestant used by millions of Americans to treat nasal congestion doesn't actually work

Barchart · Sep 6, 2023

Unusual Options Activity in Johnson & Johnson Post Its Kenvue Spinoff Highlights Its Value

An unusual number of out-of-the-money put options in Johnson & Johnson come after the Aug. 30 spinoff of its consumer Kenvue business. This could be a good income play for short-put traders.

1 … 11 12 13 14

Coverage From

People

Dipanjan BanchurSince

722 stories

Harmanpreet Kaur

666 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.